Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Issue 1 (13th April 2019)

• Record Type: Journal Article
• Authors: Brown, Jacob T.; Bishop, Jeffrey R.; Sangkuhl, Katrin; Nurmi, Erika L.; Mueller, Daniel J.; Dinh, Jean C.; Gaedigk, Andrea; Klein, Teri E.; Caudle, Kelly E.; McCracken, James T.; de Leon, Jose; Leeder, J. Steven
• Is Part Of: Clinical pharmacology & therapeutics. Volume 106:Issue 1(2019)
• Page Start: 94
• Page End: 102
• Publication Date: 2019-04-13
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1409
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity disorder (ADHD). Cytochrome P450 ( CYP ) 2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org ).